MDX-210 bispecific antibody: Phase II trial in the U.K.

Medarex Inc. (MEDX), Annadale, N.J. Product: MDX-210 bispecific antibody Indication: Prostate cancer Status: MEDX and partner Ciba-Geigy began a Phase II trial in the U.K. to test efficacy and safety....